When is CAR T-cell therapy recommended for multiple myeloma?

T cells are collected from the blood and changed in a laboratory to recognise a target on myeloma cells. After preparation treatment, the modified cells are returned to the body. The myeloma team reviews the treatments already tried, how quickly the disease has returned, blood counts, kidney and heart function, infection history and ability to attend intensive follow-up.

The immune response may cause fever, low blood pressure, breathing problems, low blood counts or neurological symptoms. The treatment centre will explain monitoring, medicines and when to remain near the hospital.

Ask whether CAR T-cell therapy fits your myeloma history and whether the relevant target is present. Review other available treatments, cell collection, preparation therapy, infection prevention, transfusion needs and caregiver arrangements. Tell the team about bone pain, weakness, fever, recent infections and every medicine or supplement you take.

Seek urgent advice for fever, chills, faintness, new confusion, difficulty speaking, severe drowsiness, seizure or breathing difficulty during or after treatment. Myeloma can also affect bones and kidneys, so report sudden severe back pain, new weakness, reduced urine or inability to keep fluids down without delay.

Ask why this treatment is being considered now, whether testing confirms the target, how collection may affect current therapy, and what monitoring and help at home are needed. Ask how the team will follow the myeloma and what alternatives exist if CAR T-cell therapy is unsuitable.